Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
2023年9月25日 - 11:00PM
Leiden, The Netherlands, September 25,
2023: Pharming Group N.V. (“Pharming” or “the Company”)
(Euronext: PHARM/Nasdaq: PHAR) announces today that the
Extraordinary General Meeting of Shareholders (EGM) has adopted all
proposals on the EGM agenda.
Shareholders approved the appointment of Dr.
Richard Peters as Non-Executive director for a period of four
years. As a result, Dr. Peters succeeds Mr. Paul Sekhri as Chair of
the Board of Directors with immediate effect.
Deborah Jorn, Vice-Chair of the Board of
Directors, commented:
“On behalf of the Board, I would like to thank
our outgoing Chairman, Paul Sekhri, for his leadership, over the
past eight years. During his tenure as Chairman, Paul accomplished
many strategic objectives and leaves Pharming in a strong position
for his successor, Dr. Richard Peters.
We welcome Dr. Richard Peters onto the Board and
we look forward to working with him over the next four years to
deliver on Pharming’s current objectives and to further strengthen
the company’s position in the rare disease market.”
Sijmen de Vries, Executive Director &
Chief Executive Officer, commented:
“I’d like to thank Paul Sekhri for his
dedication and leadership over the past eight years. Amongst his
many accomplishments, he was instrumental in buying back the U.S.
commercialization rights for RUCONEST®, and helped pave the way for
Pharming’s transformation into a successful commercial stage rare
disease company.
As we look to the future, we are excited to
welcome Dr. Richard Peters as our new Chairman. His extensive
medical and commercial experience is a great asset to the Board.
His leadership will be an intrinsic part of meeting our strategic
corporate objectives as we move into Pharming’s next stage of
growth; a company with multiple products in multiple geographies. I
look forward to working closely with Dr. Peters and the rest of the
Board, as we continue to pursue our mission of serving the global
unserved rare disease patient.”
In addition, shareholders also approved the
proposal for the annual fee increase payable to the Chair of the
Board of Directors.
A recording of the webcast, presentation slides
from today’s EGM, and more details regarding both agenda items are
available on the Company’s website in the Investor Relations
section.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam:
PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated
to transforming the lives of patients with rare, debilitating, and
life-threatening diseases. Pharming is commercializing and
developing an innovative portfolio of protein replacement therapies
and precision medicines, including small molecules, biologics, and
gene therapies that are in early to late-stage development.
Pharming is headquartered in Leiden, Netherlands, and has employees
around the globe who serve patients in over 30 markets in North
America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and
find us on LinkedIn.
Inside Information
This press release relates to the disclosure of
information that qualifies, or may have qualified, as inside
information within the meaning of Article 7(1) of the EU Market
Abuse Regulation.
For further public information,
contact:
Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications T: +1 (908) 705 1696
Heather Robertson, Investor Relations &
Corporate Communications Manager E: investor@pharming.com
FTI Consulting, London, UK Victoria Foster
Mitchell/Alex Shaw/Amy Byrne T: +44 203 727 1000
LifeSpring Life Sciences Communication,
Amsterdam, The Netherlands Leon Melens T: +31 6 53 81 64 27 E:
pharming@lifespring.nl
Pharming Group NV (EU:PHARM)
過去 株価チャート
から 12 2024 まで 1 2025
Pharming Group NV (EU:PHARM)
過去 株価チャート
から 1 2024 まで 1 2025
